Autoimmune Diseases  >>  sifalimumab (MDX-1103)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sifalimumab (MDX-1103) / AstraZeneca
NCT01283139 / 2010-024069-30: A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Checkmark Systemic lupus erythematosus
Mar 2015 - Mar 2015: Systemic lupus erythematosus
Checkmark
Nov 2014 - Nov 2014: 
Checkmark For systemic lupus erythematosus
More
Completed
2b
834
US, Canada, Europe, RoW
Sifalimumab 200 mg, MEDI-545, Sifalimumab 600 mg, Sifalimumab 1,200 mg, Placebo
MedImmune LLC
Systemic Lupus Erythematosus
11/13
04/14
NCT00657189: A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

Checkmark Data
Apr 2011 - Apr 2011: Data
Completed
2a
87
US
MEDI-545, Placebo
MedImmune LLC
Lupus Erythematosus, Systemic, Lupus
05/10
05/10
NCT01031836: A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

Completed
2
30
Japan
MEDI-545, MEDI-545 600
AstraZeneca, MedImmune LLC
Systemic Lupus Erythematosus
11/12
07/16
NCT00979654: A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Completed
2
118
US, Canada, RoW
Sifalimumab
MedImmune LLC, PPD
Systemic Lupus Erythematosus
03/15
03/15

Download Options